Citation Impact
Citing Papers
SuFEx-enabled, agnostic discovery of covalent inhibitors of human neutrophil elastase
2019 StandoutNobel
Host age, social group, and habitat type influence the gut microbiota of wild ring‐tailed lemurs (Lemur catta)
2016 Standout
Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade
2008 Standout
d-Galactose-induced accelerated aging model: an overview
2019 Standout
The Retinal Pigment Epithelium in Visual Function
2005 Standout
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR
2015 Standout
In Vivo Characteristics of Cationic Liposomes as Delivery Vectors for Gene Therapy
2002
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Cystic fibrosis
2016 Standout
Cystic fibrosis
2003
Lipid nanoparticles for mRNA delivery
2021 Standout
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial
2014
Gold nanoparticles in delivery applications☆
2008 Standout
Aminoglycoside suppression of a premature stop mutation in a Cftr–/– mouse carrying a human CFTR-G542X transgene
2002 StandoutNobel
Genotype and Phenotype in Cystic Fibrosis
2000
Biochemical and biophysical characteristics of lipoplexes pertinent to solid tumour gene therapy
2002
PLGA-based nanoparticles: An overview of biomedical applications
2012 Standout
Design and development of polymers for gene delivery
2005 Standout
Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination
2020 StandoutNobel
Toxicity of cationic lipids and cationic polymers in gene delivery
2006 Standout
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
2011 Standout
Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems
2017
Non-viral vectors for gene-based therapy
2014 Standout
Recent advances with liposomes as pharmaceutical carriers
2005 Standout
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
2015 Standout
Processing of CFTR: Traversing the cellular maze—How much CFTR needs to go through to avoid cystic fibrosis?
2005
Nanovehicular Intracellular Delivery Systems
2008
Hidden sources of galactose in the environment
1995
Intestinal mucosal barrier function in health and disease
2009 Standout
Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis
2010
Physiology and Pathophysiology of Purinergic Neurotransmission
2007 Standout
Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues
2008 Standout
Cystic fibrosis genetics: from molecular understanding to clinical application
2014 Standout
Purinergic regulation of epithelial transport
2003
Update on Key Emerging Challenges in Cystic Fibrosis
2014 Standout
Urinary tract infections: epidemiology, mechanisms of infection and treatment options
2015 Standout
Barriers to Nonviral Gene Delivery
2003
Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis
2007
Antibacterial drug discovery in the resistance era
2016 StandoutNature
Gene transfer to the lung: Lessons learned from more than 2 decades of CF gene therapy
2008
Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis
2002
Pathogen–Host Interactions in Pseudomonas aeruginosa Pneumonia
2005
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
2003 Standout
A Pilot Study of the Effect of Gentamicin on Nasal Potential Difference Measurements in Cystic Fibrosis Patients Carrying Stop Mutations
2000
Hemolytic Phospholipase C Inhibition Protects Lung Function during Pseudomonas aeruginosa Infection
2011
Inflammatory Airway Disease of Horses—Revised Consensus Statement
2016 Standout
Compacted DNA Nanoparticles Administered to the Nasal Mucosa of Cystic Fibrosis Subjects Are Safe and Demonstrate Partial to Complete Cystic Fibrosis Transmembrane Regulator Reconstitution
2004
Differentiation of chronic sinus diseases by measurement of inflammatory mediators
2006 Standout
Nonviral Vectors for Gene Delivery
2008 Standout
Radiographic scoring lacks predictive value in inflammatory airway disease
2005
Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data
2013
Essential genome of Pseudomonas aeruginosa in cystic fibrosis sputum
2015
Role of CFTR in Airway Disease
1999
Inflammatory Bowel Disease
2010 Standout
Animal models of gastrointestinal and liver diseases. Animal models of cystic fibrosis: gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology
2015
Scalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic Device
2021 StandoutNobel
Lung Infections Associated with Cystic Fibrosis
2002 Standout
Works of Mark Weatherly being referenced
Increased frequency of cystic fibrosis among infants with jejunoileal atresia
1998
Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis**
2002
A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis*
2002
Function and Composition of Pulmonary Surfactant and Surfactant-Derived Fatty Acid Profiles Are Altered in Young Adults With Cystic Fibrosis
2000
Relationship between airway ion transport and a mild pulmonary disease mutation in CFTR.
1997
A Clinical Inflammatory Syndrome Attributable to Aerosolized Lipid–DNA Administration in Cystic Fibrosis
2001
Sweeteners, Flavorings, and Dyes in Antibiotic Preparations
1991
Wisconsin Cystic Fibrosis Chest Radiograph Scoring System
1993